"Path of the Heart" (The BPROAD Study) Addresses Optimal Systolic Blood Pressure for Patients With Diabetes

Ning Guang^{1

2}

Affiliations

¹ Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
² National Clinical Research Center for Metabolic Diseases (Shanghai), Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, National Research Center for Translational Medicine, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Editorial

Ning Guang. J Diabetes. 2025 Jan.

. 2025 Jan;17(1):e70053.

doi: 10.1111/1753-0407.70053.

Ning Guang^{1

2}

¹ Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
² National Clinical Research Center for Metabolic Diseases (Shanghai), Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, National Research Center for Translational Medicine, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

No abstract available

Conflict of interest statement

The author declares no conflicts of interest.

1. Bi Y., Li M., Liu Y., et al., “Intensive Blood‐Pressure Control in Patients With Type 2 Diabetes,” New England Journal of Medicine (2024), 10.1056/NEJMoa2412006. - DOI - PubMed
1. SPRINT Research Group , Wright J. T., Williamson J. D., et al., “A Randomized Trial of Intensive Versus Standard Blood‐Pressure Control,” New England Journal of Medicine 373, no. 22 (2015): 2103–2116, 10.1056/NEJMoa1511939. - DOI - PMC - PubMed
1. SPRINT Research Group , Lewis C. E., Fine L. J., et al., “Final Report of a Trial of Intensive Versus Standard Blood‐Pressure Control,” New England Journal of Medicine 384, no. 20 (2021): 1921–1930, 10.1056/NEJMoa1901281. - DOI - PMC - PubMed
1. ACCORD Study Group , Cushman W. C., Evans G. W., et al., “Effects of Intensive Blood‐Pressure Control in Type 2 Diabetes Mellitus,” New England Journal of Medicine 362, no. 17 (2010): 1575–1585, 10.1056/NEJMoa1001286. - DOI - PMC - PubMed
1. BPROAD Study Group , “Rationale and Design for the Blood Pressure Control Target in Diabetes (BPROAD) Study,” Journal of Diabetes 15, no. 12 (2023): 1029–1040, 10.1111/1753-0407.13411. - DOI - PMC - PubMed